NEW YORK (GenomeWeb News) — ProMetic BioSciences has sold CA$3.9 million ($3.4 million) worth of its mimetic ligand affinity adsorbent product to an “existing multinational” client, the company said today.
 
ProMetic Bio, a division of ProMetic Life Sciences, said it will supply the products in the first and second quarters of 2007.
 
Earlier this month, ProMetic said it would develop synthetic ligands for Novartis' vaccine program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.